Gross Tumor Volume (GTV)

The Gross Tumor Volume (GTV) represents the demonstrable extent and location of the primary tumor. It is defined through clinical examination (inspection, palpation) and imaging modalities. The GTV is a purely anatomical-anatomical concept, distinct from microscopic spread. Key characteristics:

• Primary GTV: The main tumor mass.
• Nodal GTV: Metastatic regional lymph nodes.
• Distant Metastasis GTV: Discrete distant lesions.
• If the tumor is surgically removed, no GTV exists, and the target becomes the Clinical Target Volume (CTV).

Accurate GTV contouring relies on fusing multiple imaging modalities to overcome the limitations of any single scan. The choice depends on the tumor site and histology:

• CT (Computed Tomography): The standard for electron density calculation but often has poor soft-tissue contrast.
• MRI (Magnetic Resonance Imaging): Superior soft-tissue contrast for brain, head/neck, and pelvic tumors.
• PET (Positron Emission Tomography): Provides metabolic information, helping distinguish active tumor from atelectasis or necrosis.
• Multi-modal registration (e.g., PET/CT, MRI/CT) is essential for precise target volume definition.

The International Commission on Radiation Units and Measurements (ICRU) establishes a systematic approach to target volumes in Reports 50, 62, and 83. The GTV is the first volume defined in this hierarchy:

• GTV: Gross demonstrable tumor.
• CTV (Clinical Target Volume): GTV + margin for subclinical microscopic spread.
• PTV (Planning Target Volume): CTV + margin for geometric uncertainties (setup error, organ motion). This cascade ensures the high-dose region covers the known disease while accounting for invisible extension and physical variability.

Inter-observer variability in GTV contouring is a major source of systematic error in radiotherapy. Consequences include:

• Geographic miss: Under-contouring leads to tumor underdosage and local recurrence.
• Normal tissue toxicity: Over-contouring increases the dose to adjacent Organs-at-Risk (OARs).
• Quantified impact: Studies show standard deviation of 2-5 mm for inter-physician contouring, which can significantly alter tumor control probability (TCP).
• AI-assisted auto-segmentation aims to reduce this variability by providing consistent, evidence-based contours.

While GTV is purely anatomical, the Biological Target Volume (BTV) integrates functional or molecular imaging to identify sub-regions of the tumor with specific biological characteristics:

• Hypoxic sub-volumes: Identified via FMISO-PET, potentially requiring a radiation boost.
• High-proliferation regions: Detected by FLT-PET.
• Cellular density: Mapped via diffusion-weighted MRI (ADC maps). The BTV concept allows for dose painting, where the prescription dose is non-uniformly escalated within the GTV based on biological risk.

Convolutional neural networks, particularly U-Net and nnU-Net architectures, are now state-of-the-art for automatic GTV delineation. These models learn from expert-annotated datasets to predict voxel-level tumor masks.

• Input: Multi-modal imaging volumes (CT, MRI, PET).
• Output: A binary or probabilistic 3D segmentation mask.
• Advantage: Reduces contouring time from hours to minutes and minimizes inter-observer variability.
• Challenge: Requires large, high-quality annotated datasets and robust generalization across scanner types and protocols.

A tissue volume containing the GTV plus a margin for subclinical microscopic disease spread. The CTV is a geometric expansion of the GTV, accounting for the tumor's typical patterns of local invasion. Unlike the GTV, the CTV is not directly visible on imaging—it is a probabilistic construct based on histopathological evidence of tumor extension beyond the macroscopic boundary. Key characteristics:

• Defined by radiation oncologists using anatomical knowledge
• Typically extends 5-15 mm beyond GTV depending on tumor histology
• Must respect anatomical barriers (bone, fascia) that block tumor spread

A geometric expansion of the CTV that accounts for setup uncertainties and organ motion during treatment. The PTV ensures the CTV receives the prescribed dose despite daily variations in patient positioning and internal anatomy. Sources of uncertainty:

• Inter-fraction motion: Bladder filling, bowel gas, weight changes
• Intra-fraction motion: Respiratory movement, cardiac pulsation
• Setup errors: Laser alignment, couch positioning tolerances PTV margins are calculated using systematic and random error statistics from population-based studies.

The delineation of healthy anatomical structures whose radiation tolerance constrains the dose that can be safely delivered to the GTV. OARs are segmented alongside the GTV to enable dose-volume histogram (DVH) optimization. Critical OARs by site:

• Head & neck: Brainstem, optic chiasm, parotid glands, spinal cord
• Thorax: Lungs, heart, esophagus, brachial plexus
• Pelvis: Bladder, rectum, femoral heads, bowel bag Dose constraints are expressed as maximum point doses or volume-at-dose thresholds (e.g., V20Gy < 30%).

A sub-volume within the GTV identified through functional or molecular imaging that may require a radiation boost due to radio-resistance or high clonogen density. BTVs are derived from modalities beyond anatomical CT: FDG-PET for metabolic activity, FMISO-PET for hypoxia, or multiparametric MRI for cellularity. Clinical rationale:

• Hypoxic tumor regions are 2-3x more radio-resistant
• Dose painting to BTV may improve local control
• Requires validated imaging biomarkers and dose-painting protocols

A volume that encompasses the GTV plus an internal margin (IM) to account for physiological motion during imaging and treatment. The ITV is distinct from the PTV—it addresses internal organ displacement rather than setup errors. Motion management techniques:

• 4D-CT: Captures respiratory phases for ITV generation
• Gating: Beam-on only during specific breathing phases
• Tracking: Real-time tumor position monitoring ITV-based planning is common in lung and liver SBRT where respiratory excursion is significant.